Approved HIV Drugs
Approved HIV Drugs
EACS 2015: Can Dolutegravir Dual Therapy or Monotherapy Keep HIV Suppressed?
- Details
- Category: Approved HIV Drugs
- Published on Thursday, 22 October 2015 00:00
- Written by Liz Highleyman
The potent integrase inhibitor dolutegravir taken with a single well-tolerated NRTI was able to fully suppress viral load in people initiating antiretroviral treatment for the first time, while dolutegravir alone was able to keep HIV suppressed in most treatment-experienced people who started with undetectable viral load, according to a set of studies presented at the 15th European AIDS Conference this week in Barcelona. After these presentations experts offered evidence in favor of and opposed to simplifying treatment by reducing drug burden, disagreeing about whether this strategy is beneficial or too risky.
IAS 2015: Rilpivirine + Darunavir HIV Maintenance Regimen Matches Standard 3-Drug ART
- Details
- Category: Approved HIV Drugs
- Published on Tuesday, 08 September 2015 00:00
- Written by Liz Highleyman
A NRTI-sparing dual antiretroviral regimen consisting of the NNRTI rilpivirine (Edurant) plus the boosted HIV protease inhibitor darunavir (Prezista) maintained viral suppression and was well-tolerated by people who switched from a standard 3-drug regimen, according to results from the PROBE study presented at the recent 8th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention in Vancouver.
CROI 2015: Does Emtricitabine Work Better than Lamivudine in Combination ART?
- Details
- Category: Approved HIV Drugs
- Published on Friday, 20 March 2015 00:00
- Written by Liz Highleyman
People with HIV who started an antiretroviral regimen containing emtricitabine (FTC; Emtriva) and NNRTIs were about half as likely to experience virological treatment failure as those who used the similar drug lamivudine (3TC; Epivir), according to an analysis of more than 6000 participants in the Dutch ATHENA cohort presented at the recent 2015 Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle. No significant differences between emtricitabine and lamivudine were seen with boosted protease inhibitor regimens.
IAS 2015: WAVES Shows Elvitegravir Regimen Beats Boosted Atazanavir for Women with HIV
- Details
- Category: Approved HIV Drugs
- Published on Wednesday, 05 August 2015 00:00
- Written by Liz Highleyman
A study of antiretroviral treatment specifically for women with HIV showed that a single-tablet regimen containing the integrase inhibitor elvitegravir suppressed the virus better than a regimen containing ritonavir-boosted atazanavir, according to a poster presented at the 8th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention last month in Vancouver. This study is important in part because it demonstrates that including more women in clinical trials is feasible.
CROI 2015: Antiretroviral Therapy -- Past, Present and Future [VIDEO]
- Details
- Category: Approved HIV Drugs
- Published on Monday, 09 March 2015 00:00
- Written by Gregory Fowler
Antiretroviral therapy (ART) has undergone a remarkable evolution from AZT monotherapy in the late 1980s, to effective combination therapy in the mid-1990s, to today's well-tolerated single-tablet regimens. But questions about the optimal time to start treatment remain unanswered and getting ART to everyone who needs it is still a challenge, according to a presentation by David Cooper at the recent 2015 Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle.
Web Design and Development by